Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 4/20 | 0.40 |
| ▸ | ESRRG | P62508 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568186 | 0.85 | AURKA (0.45) | MCHR1CHRM1HTR2AHRH3AURKA | |
| SCHEMBL3568181 | 0.85 | AURKA (0.45) | MCHR1CHRM1HTR2AHRH3AURKA | |
| SCHEMBL13034751 | 0.80 | TGFBR1 (0.45) | HRH3MAPK7TGFBR1 | |
| SCHEMBL3574118 | 0.80 | AURKA (0.49) | HRH3AURKASPHK1 | |
| SCHEMBL3574113 | 0.80 | AURKA (0.49) | HRH3AURKASPHK1 | |
| SCHEMBL12049876 | 0.79 | IDO1 (0.41) | AURKAMAPK7 | |
| SCHEMBL13034746 | 0.79 | POLB (0.44) | HRH3MAPK7 | |
| SCHEMBL13034748 | 0.77 | MET (0.47) | HTR2AHRH3AURKAKCNH2TGFBR1 | |
| SCHEMBL4965317 | 0.72 | MAPK7 (0.45) | MCHR1CHRM1HTR2AHRH3AURKA | |
| SCHEMBL5604728 | 0.72 | MAPK7 (0.45) | MCHR1CHRM1HTR2AHRH3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825244-B2 | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021436-A1 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS | FLT3, ABL1, KIT | MCHR1 1470/4885CHRM1 1033/4885HTR2A 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.